Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.
Kimberley S MakMolly Scannell BryanJames J DignamWilliam U ShipleyYue LinChristopher A PetersElizabeth M GoreSeth A RosenthalKenneth L ZeitzerDavid P D'SouzaEric M HorwitzThomas M PisanskyJordan M MaierSusan M ChafeTyler P RobinMack RoachPhuoc T TranLuis SouhamiJeff M MichalskiAlan C HartfordFelix Y FengHoward M SandlerJason A EfstathiouPublished in: European urology focus (2024)
In a long-term analysis of a large randomized prostate cancer trial, radiation with 28 mo of hormone therapy did not increase the risk of cardiovascular death significantly versus 4 mo of hormone therapy. Future studies are needed for patients with pre-existing heart disease, who may have an increased risk of myocardial infarction death with longer hormone use.
Keyphrases
- prostate cancer
- radical prostatectomy
- phase iii
- locally advanced
- phase ii
- squamous cell carcinoma
- clinical trial
- open label
- heart failure
- double blind
- rectal cancer
- neoadjuvant chemotherapy
- cardiovascular events
- study protocol
- cardiovascular disease
- randomized controlled trial
- placebo controlled
- stem cells
- current status
- type diabetes
- risk factors
- radiation induced
- atrial fibrillation